EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine

by Vandana Singh, Benzinga Editor

September 9, 2021 2:41 PM | 1 min read | Make a Comment

European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc PFE and BioNTech SE BNTX.
One site, located in Frankfurt, is operated by Sanofi-Aventis Deutschland GmbH, part of Sanofi SA SNY. The other in Hameln is operated by Siegfried Hameln GmbH. Both sites will manufacture the finished product.
These sites will provide up to 50 million additional doses in 2021.
Read Next: EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines.
Price Action: PFE shares are down 1.29% at $45.91, while BNTX stock is up 3.88% at $349.29 during the market session on the last check Thursday.

Posted In: Biotech News Health Care FDA Movers Trading Ideas General Briefs COVID-19 Coronavirus COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.